Atea Pharmaceuticals Provides Update and Topline Results for Phase 2 MOONSONG Trial Evaluating AT-527 in the Outpatient SettingGlobeNewsWire • 10/19/21
Atea Pharmaceuticals to Present at Guggenheim 2nd Annual Vaccines & Infectious Day ConferenceGlobeNewsWire • 09/29/21
Atea Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare ConferenceGlobeNewsWire • 09/07/21
Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752's Potent In Vitro and In Vivo Activity Against Dengue and Other FlavivirusesGlobeNewsWire • 08/24/21
Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/13/21
Atea Pharmaceuticals to Host Second Quarter Financial Results Conference Call on August 12, 2021GlobeNewsWire • 08/05/21
This High-Risk, High-Reward Biotech Could Make COVID Less Deadly -- and Make Investors MoneyThe Motley Fool • 08/04/21
Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 PatientsBenzinga • 06/30/21
Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with RocheGlobeNewsWire • 06/16/21
Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical AffairsGlobeNewsWire • 06/15/21
Atea Pharmaceuticals Appoints Jerome Adams, M.D., M.P.H., to Board of DirectorsGlobeNewsWire • 05/20/21
Atea Pharmaceuticals, Inc.'s (AVIR) CEO Jean-Pierre Sommadossi on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/14/21